Clinical Trials Logo

Pulmonary Hypertension clinical trials

View clinical trials related to Pulmonary Hypertension.

Filter by:

NCT ID: NCT03122730 Completed - Clinical trials for Pulmonary Hypertension

VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB

Start date: August 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2) demonstrate that an optimum effect can be rapidly obtained with VentaProst titration.

NCT ID: NCT03077139 Completed - Clinical trials for Pulmonary Hypertension

Cardiac Resynchronization Therapy in Pulmonary Hypertension

CRT in PH
Start date: November 29, 2012
Phase: N/A
Study type: Interventional

This study is being conducted to determine whether patients with advanced pulmonary hypertension when treated with cardiac resynchronization therapy improve hemodynamically and/or receive clinical benefit.

NCT ID: NCT03045614 Completed - Clinical trials for Pulmonary Hypertension

Kidney Disease and Pulmonary Hypertension

Start date: February 1, 2017
Phase:
Study type: Observational

Evaluation of the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome in patients with invasively diagnosed pulmonary hypertension.

NCT ID: NCT03039972 Completed - Clinical trials for Pulmonary Hypertension

Changes in Renal Function and Body Composition in Pulmonary Hypertension

Start date: January 25, 2017
Phase:
Study type: Observational [Patient Registry]

Changes in renal function and body composition in patients with pulmonary hypertension

NCT ID: NCT03039959 Completed - Heart Failure Clinical Trials

Predictive Value of Renal Venous Flow Profiles for Adverse Outcomes in Right Heart Failure

Start date: November 2016
Phase:
Study type: Observational [Patient Registry]

Predictive value of renal venous flow profiles for adverse outcomes in patients with right heart failure

NCT ID: NCT03030807 Completed - Clinical trials for Pulmonary Hypertension

Pulmonary Hypertension in Hypersensitivity Pneumonitis

Start date: October 2016
Phase:
Study type: Observational

The investigation serves the identification of pulmonary hypertension (PH) among patients with hypersensitivity pneumonitis (HP). The exact prevalence of PH in HP is unknown. Data from South America indicate that the prevalence of pre-capillary PH amongst patients with HP is higher than 20%. There are no reliable data from Europe so far. According to the investigators previous analysis, more than 400 HP patients have participated in pulmonary rehabilitation at least once in the past 10 years at Klinikum Bad Gleichenberg (Rehabilitation Center for Agricultural Workers in Austria). This collective of patients is to be invited to participate in the study. A diagnostic algorithm will be applied in the clinical trial, in the case of clinical suspicion the diagnosis of PH will be confirmed by right heart catheterization. Besides the determination of the prevalence of PH in patients with HP the investigators aim to assess the reliability of non-invasive methods (e.g. Echocardiography, ECG...) to predict PH.

NCT ID: NCT02999438 Completed - Heart Failure Clinical Trials

Frailty in Children With Cardiac Disease

Start date: November 2016
Phase:
Study type: Observational

Frailty is a complex biologic syndrome of diminished physiologic reserve that leads to decreased resistance to stressors and is associated with adverse health outcomes. The syndrome has been well studied in adults and is quantified by the Fried criteria, which are comprised of five components- slowness, weakness, self-reported exhaustion, shrinkage and diminished physical activity. The concept of frailty is novel in children. A study in young adult childhood cancer survivors demonstrated increased incidence of frailty in this population along with increased risk of morbidity and mortality. This suggests that frailty as a phenotype has relevance outside of the geriatric age group. Pediatric patients with single ventricle physiology, heart failure and pulmonary artery hypertension- all represent populations with significantly increased risk of mortality, morbidity and decreased quality of life. Currently, such patients are monitored outpatient by serial echocardiograms and blood work that only gives information about end organ damage. But there is no validated tool available to measure global infirmity in such children. Better understanding of the relevance and applicability of frailty in pediatrics may allow for identification of the most vulnerable pediatric cardiac patients and be of value in optimizing their clinical management and improving health outcomes.

NCT ID: NCT02980068 Completed - Heart Failure Clinical Trials

A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction

PMED
Start date: August 28, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in healthy adult normal volunteers compared to volunteers with PH-HFpEF in the breakdown of oral nitrate.

NCT ID: NCT02951104 Completed - Clinical trials for Pulmonary Hypertension

Noninvasive Cardiac Output Monitoring in Pulmonary Hypertension

Start date: November 2016
Phase: N/A
Study type: Interventional

Comparison of Ultrasonic Cardiac Output Monitor (USCOM) system with Fick and thermodilution methods during right heart catheterization in patients with pulmonary hypertension.

NCT ID: NCT02892981 Completed - Clinical trials for Pulmonary Hypertension

Dead Space Evaluation in Pulmonary Hypertension

Start date: January 2015
Phase: N/A
Study type: Interventional

Aim of the study is to evaluate the role of chemoreceptor activity and ventilation perfusion mismatch on the genesis of exercise induced hyperventilation in Pulmonary hypertension patients. So the investigators tested the chemoreceptor response at rest, both with hypoxic and hypercapnic stimuli, and the ventilatory response during exercise analyzing its two components, alveolar and dead space ventilation.